With the advent of ICI therapy and emerging ICI combination therapies, clinicians need to have knowledge of where and how maintenance therapy may play a role in improving PFS in EC. During this podcast, international gynecologic cancer experts Drs. Richard Penson and Nicoletta Colombo discuss the most recent data from these EC trials, focusing on how it has changed recommended practice patterns and how it should be incorporated into the care of patients with EC.
Richard T. Penson, MD, MRCP, is a Medical Oncologist at Massachusetts General Hospital, and Associate Professor of Medicine at Harvard Medical School. A key opinion leader, Dr. Penson was a longstanding member of the Gynecologic Oncology Group Ovarian and Quality of Life Committees and now serves on the Foundation’s Investigator Council. He is the national Principal Investigator (PI) of the olaparib registration trial (SOLO-2) and the international PI of SOLO3, and the OVAL trial. He has taught on Harvard’s Practice of Medicine Course, the Bigelow General Medical Service at Massachusetts General Hospital, and is one of the Chairs of the Institutional Review Board of Dana-Farber Harvard Cancer Center.
During this informational podcast, leading international endometrial cancer experts, Drs. Richard Penson and Mansoor Raza Mirza, will discuss patient selection for upfront immunotherapy-based strategies, emerging front-line therapeutic approaches, and challenges adapting to the evolving standards of front-line care.
Richard T. Penson, MD, MRCP, is a Medical Oncologist at Massachusetts General Hospital, and Associate Professor of Medicine at Harvard Medical School. A key opinion leader, Dr. Penson was a longstanding member of the Gynecologic Oncology Group Ovarian and Quality of Life Committees and now serves on the Foundation’s Investigator Council. He is the national Principal Investigator (PI) of the olaparib registration trial (SOLO-2) and the international PI of SOLO3, and the OVAL trial. He has taught on Harvard’s Practice of Medicine Course, the Bigelow General Medical Service at Massachusetts General Hospital, and is one of the Chairs of the Institutional Review Board of Dana-Farber Harvard Cancer Center.
Multiple clinical practice guidelines for the treatment of endometrial cancer (EC) recommend consideration of molecular testing, particularly for high-grade tumors. Yet despite its prognostic value, molecular classification is not always a part of standard risk assessment in EC. Clinical uptake has been highly variable, particularly in limited-resource areas, even though recent data shows molecular classification has value in therapeutic decision-making and is prognostic for treatment response in EC. Lack of clinical uptake has resulted in overtreatment of some EC patients and undertreatment of others.
During this informational podcast, leading national endometrial cancer experts, Drs. Richard Penson and Matthew Powell, will discuss molecular classification of EC and the clinical data supporting it’s value in EC care.
Richard T. Penson, MD, MRCP, is a Medical Oncologist at Massachusetts General Hospital, and Associate Professor of Medicine at Harvard Medical School. A key opinion leader, Dr. Penson was a longstanding member of the Gynecologic Oncology Group Ovarian and Quality of Life Committees and now serves on the Foundation’s Investigator Council. He is the national Principal Investigator (PI) of the olaparib registration trial (SOLO-2) and the international PI of SOLO3, and the OVAL trial. He has taught on Harvard’s Practice of Medicine Course, the Bigelow General Medical Service at Massachusetts General Hospital, and is one of the Chairs of the Institutional Review Board of Dana-Farber Harvard Cancer Center.
In the final episode of this CMEOCast podcast series, expert faculty will discuss the use of deep neuromuscular blockade to facilitate optimal surgical conditions and provide learners with strategies to effectively utilize best practices in the pharmacologic reversal of neuromuscular blockade ideally guided by quantitative monitoring techniques.
Dr. Ian Makey is a cardiothoracic surgeon at Mayo Clinic Florida. He specializes in robotic thoracic surgery and lung transplantation.
Dru is an academic and clinically-practicing Certified Registered Nurse Anesthetist (CRNA) and American Association of Nurse Anesthesiology (AANA) President. He also serves as co-chair of the Cochrane US Network.
Ross Renew, MD, FASA, FASE, graduated from Clemson University (Chemistry, BS) and completed medical school at the University of South Carolina School of Medicine. Dr. Renew completed anesthesia residency at Mayo Clinic Florida and his fellowship in adult cardiothoracic anesthesiology at Mayo Clinic in Rochester, MN. Dr. Renew then returned to Jacksonville and has worked on staff at Mayo Clinic Florida, where he is currently an Associate Professor of Anesthesiology. Dr. Renew serves as the Vice Chair of Research and Associate Program Director for the department’s residency program. His research interests involve neuromuscular blockade and monitoring, transesophageal echocardiography, and caring for the cardiac patient undergoing non-cardiac surgery.
In the first episode of this CMEOCast podcast series, Dr. Faulk and Dr. Renew will help learners to translate data into clinical practice regarding the differences between clinical assessment, qualitative assessment, and quantitative TOF monitoring and their efficacy in detecting residual neuromuscular blockade.
Dr. Debra Faulk is an associate professor of pediatric anesthesiology and board-certified pediatric anesthesiologist. Her interests include sedation, simulation, pre-operative anxiety, and emergence agitation in kids. Dr. Faulk’s current research is in the monitoring of neuromuscular blockade in pediatric anesthesia, including studies looking a residual neuromuscular blockade as well as validation of objective EMG monitoring and their use for appropriate dosing of sugammadex in children.
Ross Renew, MD, FASA, FASE, graduated from Clemson University (Chemistry, BS) and completed medical school at the University of South Carolina School of Medicine. Dr. Renew completed anesthesia residency at Mayo Clinic Florida and his fellowship in adult cardiothoracic anesthesiology at Mayo Clinic in Rochester, MN. Dr. Renew then returned to Jacksonville and has worked on staff at Mayo Clinic Florida, where he is currently an Associate Professor of Anesthesiology. Dr. Renew serves as the Vice Chair of Research and Associate Program Director for the department’s residency program. His research interests involve neuromuscular blockade and monitoring, transesophageal echocardiography, and caring for the cardiac patient undergoing non-cardiac surgery.
In the second episode of the CMEOCast podcast series, J.Ross Renew, MD and Dru Riddle, DNP, CRNA will guide learners through strategies to best incorporate recommendations from the 2023 ASA guidelines into clinical practice.
Dru is an academic and clinically-practicing Certified Registered Nurse Anesthetist (CRNA) and American Association of Nurse Anesthesiology (AANA) President. He also serves as co-chair of the Cochrane US Network.
Ross Renew, MD, FASA, FASE, graduated from Clemson University (Chemistry, BS) and completed medical school at the University of South Carolina School of Medicine. Dr. Renew completed anesthesia residency at Mayo Clinic Florida and his fellowship in adult cardiothoracic anesthesiology at Mayo Clinic in Rochester, MN. Dr. Renew then returned to Jacksonville and has worked on staff at Mayo Clinic Florida, where he is currently an Associate Professor of Anesthesiology. Dr. Renew serves as the Vice Chair of Research and Associate Program Director for the department’s residency program. His research interests involve neuromuscular blockade and monitoring, transesophageal echocardiography, and caring for the cardiac patient undergoing non-cardiac surgery.